Showing results (1361-1370 of 5,058) with videos related to

Sort By:
Pageof 506
Multiple Sclerosis and Related Disorders|September 23, 2019
Rituximab-induced serum sickness in multiple sclerosis patientsAndrew B Wolf, Lana Zhovtis Ryerson, Krupa Pandey, et al.
Multiple Sclerosis and Related Disorders|August 18, 2019
Circulating mesenchymal stem cells, stromal derived factor (SDF)-1 and IP-10 levels increased in clinically active multiple sclerosis patients but not in clinically stable patients treated with beta interferonRahimeh Emamnejad, Mohammadali Sahraian, Yadollah Shakiba, et al.
Multiple Sclerosis and Related Disorders|August 18, 2019
Rash developing after cessation of Daclizumab for relapsing remitting MS; a case seriesAndrew Lockhart, Brian Kirby, Christopher McGuigan
Multiple Sclerosis and Related Disorders|August 20, 2019
Effectiveness and tolerability of immunosuppressants and monoclonal antibodies in preventive treatment of neuromyelitis optica spectrum disorders: A systematic review and network meta-analysisWenjuan Huang, Liang Wang, Baojingzi Zhang, et al.
Multiple Sclerosis and Related Disorders|October 3, 2019
Role of B cells and antibodies in multiple sclerosisPitchaya Wanleenuwat, Piotr Iwanowski
Multiple Sclerosis and Related Disorders|March 2, 2019
Highly active multiple sclerosis: An updateCindy Díaz, Luis Alfonso Zarco, Diego M Rivera
Multiple Sclerosis and Related Disorders|February 15, 2019
Time between expanded disability status scale (EDSS) scoresJonathan Zurawski, Bonnie I Glanz, Alicia Chua, et al.
Multiple Sclerosis and Related Disorders|March 11, 2019
Does cognitive reserve play any role in multiple sclerosis? A meta-analytic studyGabriella Santangelo, Manuela Altieri, Antonio Gallo, et al.
Multiple Sclerosis and Related Disorders|February 21, 2019
Associations of demographic and clinical factors with depression over 2.5-years in an international prospective cohort of people living with MSSteve Simpson, Keryn L Taylor, George A Jelinek, et al.
Multiple Sclerosis and Related Disorders|February 21, 2019
The value of anti-JCV antibody index assessment in multiple sclerosis patients treated with natalizumab with respect to demographic, clinical and radiological findingsJan Kolcava, Monika Hulova, Yvonne Benesova, et al.
Pageof 506